FDA Grants Fast Track Designation to Oral Treatment for Retinitis Pigmentosa
Nacuity’s NPI-001 investigational mutation-agnostic oral tablet therapy for retinitis pigmentosa has been greenlit for speedier approval by the FDA. The…
Nanoscope Therapeutics to Submit BLA for Retinitis Pigmentosa Gene Therapy Candidate MCO-010
Sparked by new 100-week data and discussions with the FDA, the company’s bid for approval in the United States will…
popular posts
latest posts